WO2022163336A1 - セラミド類含有組成物 - Google Patents
セラミド類含有組成物 Download PDFInfo
- Publication number
- WO2022163336A1 WO2022163336A1 PCT/JP2022/000499 JP2022000499W WO2022163336A1 WO 2022163336 A1 WO2022163336 A1 WO 2022163336A1 JP 2022000499 W JP2022000499 W JP 2022000499W WO 2022163336 A1 WO2022163336 A1 WO 2022163336A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- ceramides
- acid
- uronic acid
- ceramide
- composition
- Prior art date
Links
- 229940106189 ceramide Drugs 0.000 title claims abstract description 99
- 239000000203 mixture Substances 0.000 title claims abstract description 82
- YDNKGFDKKRUKPY-JHOUSYSJSA-N C16 ceramide Natural products CCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)C=CCCCCCCCCCCCCC YDNKGFDKKRUKPY-JHOUSYSJSA-N 0.000 title claims abstract description 20
- CRJGESKKUOMBCT-VQTJNVASSA-N N-acetylsphinganine Chemical compound CCCCCCCCCCCCCCC[C@@H](O)[C@H](CO)NC(C)=O CRJGESKKUOMBCT-VQTJNVASSA-N 0.000 title claims abstract description 20
- ZVEQCJWYRWKARO-UHFFFAOYSA-N ceramide Natural products CCCCCCCCCCCCCCC(O)C(=O)NC(CO)C(O)C=CCCC=C(C)CCCCCCCCC ZVEQCJWYRWKARO-UHFFFAOYSA-N 0.000 title claims abstract description 20
- VVGIYYKRAMHVLU-UHFFFAOYSA-N newbouldiamide Natural products CCCCCCCCCCCCCCCCCCCC(O)C(O)C(O)C(CO)NC(=O)CCCCCCCCCCCCCCCCC VVGIYYKRAMHVLU-UHFFFAOYSA-N 0.000 title claims abstract description 20
- 150000004676 glycans Chemical class 0.000 claims abstract description 52
- 229920001282 polysaccharide Polymers 0.000 claims abstract description 51
- 239000005017 polysaccharide Substances 0.000 claims abstract description 51
- 239000002253 acid Substances 0.000 claims abstract description 50
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims abstract description 39
- 239000013078 crystal Substances 0.000 claims abstract description 38
- 238000001556 precipitation Methods 0.000 claims abstract description 26
- 239000003125 aqueous solvent Substances 0.000 claims abstract description 21
- 229920001451 polypropylene glycol Polymers 0.000 claims abstract description 15
- 150000001783 ceramides Chemical class 0.000 claims description 79
- XDOFQFKRPWOURC-UHFFFAOYSA-N 16-methylheptadecanoic acid Chemical group CC(C)CCCCCCCCCCCCCCC(O)=O XDOFQFKRPWOURC-UHFFFAOYSA-N 0.000 claims description 49
- 238000004519 manufacturing process Methods 0.000 claims description 39
- 239000002537 cosmetic Substances 0.000 claims description 36
- 239000002736 nonionic surfactant Substances 0.000 claims description 28
- 229920002674 hyaluronan Polymers 0.000 claims description 24
- 238000002360 preparation method Methods 0.000 claims description 22
- 229960003160 hyaluronic acid Drugs 0.000 claims description 18
- 238000010438 heat treatment Methods 0.000 claims description 16
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical group CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims description 13
- 238000000034 method Methods 0.000 claims description 13
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 claims description 12
- 229920002385 Sodium hyaluronate Polymers 0.000 claims description 11
- 238000002156 mixing Methods 0.000 claims description 11
- 229940010747 sodium hyaluronate Drugs 0.000 claims description 11
- SZXQTJUDPRGNJN-UHFFFAOYSA-N dipropylene glycol Chemical compound OCCCOCCCO SZXQTJUDPRGNJN-UHFFFAOYSA-N 0.000 claims description 10
- ATGQXSBKTQANOH-UWVGARPKSA-N N-oleoylphytosphingosine Chemical compound CCCCCCCCCCCCCC[C@@H](O)[C@@H](O)[C@H](CO)NC(=O)CCCCCCC\C=C/CCCCCCCC ATGQXSBKTQANOH-UWVGARPKSA-N 0.000 claims description 8
- 229940099417 ceramide 2 Drugs 0.000 claims description 8
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 claims description 7
- 229940044176 ceramide 3 Drugs 0.000 claims description 7
- 229940097043 glucuronic acid Drugs 0.000 claims description 5
- LCZVSXRMYJUNFX-UHFFFAOYSA-N 2-[2-(2-hydroxypropoxy)propoxy]propan-1-ol Chemical compound CC(O)COC(C)COC(C)CO LCZVSXRMYJUNFX-UHFFFAOYSA-N 0.000 claims description 4
- 229920002683 Glycosaminoglycan Polymers 0.000 claims description 4
- 241000233866 Fungi Species 0.000 claims description 2
- 150000004804 polysaccharides Polymers 0.000 claims description 2
- AEMOLEFTQBMNLQ-AQKNRBDQSA-N D-glucopyranuronic acid Chemical compound OC1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-AQKNRBDQSA-N 0.000 claims 2
- KXKPYJOVDUMHGS-OSRGNVMNSA-N chondroitin sulfate Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](OS(O)(=O)=O)[C@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](C(O)=O)O1 KXKPYJOVDUMHGS-OSRGNVMNSA-N 0.000 claims 1
- 210000000434 stratum corneum Anatomy 0.000 abstract description 12
- 230000004888 barrier function Effects 0.000 abstract description 9
- 230000000694 effects Effects 0.000 abstract description 8
- -1 ceramide 2 Chemical compound 0.000 description 43
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 27
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 22
- 210000003491 skin Anatomy 0.000 description 18
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 14
- 235000014113 dietary fatty acids Nutrition 0.000 description 12
- 229930195729 fatty acid Natural products 0.000 description 12
- 239000000194 fatty acid Substances 0.000 description 12
- 235000013772 propylene glycol Nutrition 0.000 description 11
- 238000003860 storage Methods 0.000 description 10
- 238000002425 crystallisation Methods 0.000 description 9
- 230000008025 crystallization Effects 0.000 description 9
- ZFGOPJASRDDARH-UHFFFAOYSA-N 3-[[10,13-dimethyl-17-(6-methylheptan-2-yl)-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthren-3-yl]oxy]-10,13-dimethyl-17-(6-methylheptan-2-yl)-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthrene Chemical compound C12CCC3(C)C(C(C)CCCC(C)C)CCC3C2CC=C(C2)C1(C)CCC2OC1CC2=CCC3C4CCC(C(C)CCCC(C)C)C4(C)CCC3C2(C)CC1 ZFGOPJASRDDARH-UHFFFAOYSA-N 0.000 description 8
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 8
- 230000000052 comparative effect Effects 0.000 description 8
- 239000006210 lotion Substances 0.000 description 8
- 239000000047 product Substances 0.000 description 8
- 229940058015 1,3-butylene glycol Drugs 0.000 description 7
- VZSRBBMJRBPUNF-UHFFFAOYSA-N 2-(2,3-dihydro-1H-inden-2-ylamino)-N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]pyrimidine-5-carboxamide Chemical group C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C(=O)NCCC(N1CC2=C(CC1)NN=N2)=O VZSRBBMJRBPUNF-UHFFFAOYSA-N 0.000 description 7
- 235000019437 butane-1,3-diol Nutrition 0.000 description 7
- WCDDVEOXEIYWFB-VXORFPGASA-N (2s,3s,4r,5r,6r)-3-[(2s,3r,5s,6r)-3-acetamido-5-hydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4,5,6-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@@H]1C[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O)[C@H](O)[C@H]1O WCDDVEOXEIYWFB-VXORFPGASA-N 0.000 description 6
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 6
- 239000004359 castor oil Substances 0.000 description 6
- 235000019438 castor oil Nutrition 0.000 description 6
- 238000009472 formulation Methods 0.000 description 6
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 6
- 229940014041 hyaluronate Drugs 0.000 description 6
- 239000011734 sodium Substances 0.000 description 6
- 229910052708 sodium Inorganic materials 0.000 description 6
- 230000000699 topical effect Effects 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 5
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical class OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 239000002131 composite material Substances 0.000 description 5
- 238000004770 highest occupied molecular orbital Methods 0.000 description 5
- 230000003287 optical effect Effects 0.000 description 5
- 229920000223 polyglycerol Polymers 0.000 description 5
- 150000003839 salts Chemical class 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- 238000003756 stirring Methods 0.000 description 5
- 239000004094 surface-active agent Substances 0.000 description 5
- ASKIVFGGGGIGKH-UHFFFAOYSA-N 2,3-dihydroxypropyl 16-methylheptadecanoate Chemical compound CC(C)CCCCCCCCCCCCCCC(=O)OCC(O)CO ASKIVFGGGGIGKH-UHFFFAOYSA-N 0.000 description 4
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 4
- AFCARXCZXQIEQB-UHFFFAOYSA-N N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical group O=C(CCNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 AFCARXCZXQIEQB-UHFFFAOYSA-N 0.000 description 4
- 239000003945 anionic surfactant Substances 0.000 description 4
- 238000001816 cooling Methods 0.000 description 4
- 239000006071 cream Substances 0.000 description 4
- 239000002552 dosage form Substances 0.000 description 4
- 235000011187 glycerol Nutrition 0.000 description 4
- 238000004062 sedimentation Methods 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- IAJILQKETJEXLJ-QTBDOELSSA-N aldehydo-D-glucuronic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-QTBDOELSSA-N 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 230000009918 complex formation Effects 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 230000003020 moisturizing effect Effects 0.000 description 3
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 3
- 238000000879 optical micrograph Methods 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 229910052700 potassium Inorganic materials 0.000 description 3
- 238000013112 stability test Methods 0.000 description 3
- 229940104261 taurate Drugs 0.000 description 3
- AERBNCYCJBRYDG-UHFFFAOYSA-N D-ribo-phytosphingosine Natural products CCCCCCCCCCCCCCC(O)C(O)C(N)CO AERBNCYCJBRYDG-UHFFFAOYSA-N 0.000 description 2
- BBAFBDLICMHBNU-MFZOPHKMSA-N N-(2-hydroxyoctadecanoyl)-4-hydroxysphinganine Chemical compound CCCCCCCCCCCCCCCCC(O)C(=O)N[C@@H](CO)[C@H](O)[C@H](O)CCCCCCCCCCCCCC BBAFBDLICMHBNU-MFZOPHKMSA-N 0.000 description 2
- NIPNSKYNPDTRPC-UHFFFAOYSA-N N-[2-oxo-2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 NIPNSKYNPDTRPC-UHFFFAOYSA-N 0.000 description 2
- KZTJQXAANJHSCE-OIDHKYIRSA-N N-octodecanoylsphinganine Chemical compound CCCCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)CCCCCCCCCCCCCCC KZTJQXAANJHSCE-OIDHKYIRSA-N 0.000 description 2
- 229920001214 Polysorbate 60 Polymers 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 150000005215 alkyl ethers Chemical class 0.000 description 2
- 125000000217 alkyl group Chemical group 0.000 description 2
- 230000003796 beauty Effects 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- DTPCFIHYWYONMD-UHFFFAOYSA-N decaethylene glycol Polymers OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO DTPCFIHYWYONMD-UHFFFAOYSA-N 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 239000010419 fine particle Substances 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 229940074052 glyceryl isostearate Drugs 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 239000012466 permeate Substances 0.000 description 2
- AERBNCYCJBRYDG-KSZLIROESA-N phytosphingosine Chemical compound CCCCCCCCCCCCCC[C@@H](O)[C@@H](O)[C@@H](N)CO AERBNCYCJBRYDG-KSZLIROESA-N 0.000 description 2
- 229940033329 phytosphingosine Drugs 0.000 description 2
- 229920001296 polysiloxane Polymers 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 229920003169 water-soluble polymer Polymers 0.000 description 2
- WWUZIQQURGPMPG-UHFFFAOYSA-N (-)-D-erythro-Sphingosine Natural products CCCCCCCCCCCCCC=CC(O)C(N)CO WWUZIQQURGPMPG-UHFFFAOYSA-N 0.000 description 1
- BPRJQFIHEGORJE-UHFFFAOYSA-N 2-(1-hydroxypropan-2-yloxy)propan-1-ol 1-(2-hydroxypropoxy)propan-2-ol Chemical compound CC(O)COCC(C)O.CC(CO)OC(C)CO BPRJQFIHEGORJE-UHFFFAOYSA-N 0.000 description 1
- YLZOPXRUQYQQID-UHFFFAOYSA-N 3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)-1-[4-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]piperazin-1-yl]propan-1-one Chemical compound N1N=NC=2CN(CCC=21)CCC(=O)N1CCN(CC1)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F YLZOPXRUQYQQID-UHFFFAOYSA-N 0.000 description 1
- 229920001287 Chondroitin sulfate Polymers 0.000 description 1
- 239000005639 Lauric acid Substances 0.000 description 1
- WAYLDHLWVYQNSQ-KEFDUYNTSA-N N-2-hydroxylignoceroylsphingosine Chemical compound CCCCCCCCCCCCCCCCCCCCCCC(O)C(=O)N[C@@H](CO)[C@H](O)\C=C\CCCCCCCCCCCCC WAYLDHLWVYQNSQ-KEFDUYNTSA-N 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- FGUZFFWTBWJBIL-XWVZOOPGSA-N [(1r)-1-[(2s,3r,4s)-3,4-dihydroxyoxolan-2-yl]-2-hydroxyethyl] 16-methylheptadecanoate Chemical compound CC(C)CCCCCCCCCCCCCCC(=O)O[C@H](CO)[C@H]1OC[C@H](O)[C@H]1O FGUZFFWTBWJBIL-XWVZOOPGSA-N 0.000 description 1
- MIUIRGGKIICMBP-NFOZDHADSA-N [27-oxo-27-[[(2s,3s,4r)-1,3,4-trihydroxyoctadecan-2-yl]amino]heptacosyl] octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCCCCCCCCCCCCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)[C@H](O)CCCCCCCCCCCCCC MIUIRGGKIICMBP-NFOZDHADSA-N 0.000 description 1
- ZGBFGAHZKZQSLG-UMCOJZBLSA-N [30-oxo-30-[[(e,2s,3r,6r)-1,3,6-trihydroxyoctadec-4-en-2-yl]amino]triacontyl] (9z,12z)-octadeca-9,12-dienoate Chemical compound CCCCCCCCCCCC[C@@H](O)\C=C\[C@@H](O)[C@H](CO)NC(=O)CCCCCCCCCCCCCCCCCCCCCCCCCCCCCOC(=O)CCCCCCC\C=C/C\C=C/CCCCC ZGBFGAHZKZQSLG-UMCOJZBLSA-N 0.000 description 1
- 239000006096 absorbing agent Substances 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 125000004442 acylamino group Chemical group 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- IAJILQKETJEXLJ-RSJOWCBRSA-N aldehydo-D-galacturonic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-RSJOWCBRSA-N 0.000 description 1
- 125000003342 alkenyl group Chemical group 0.000 description 1
- 229940045714 alkyl sulfonate alkylating agent Drugs 0.000 description 1
- 150000008052 alkyl sulfonates Chemical class 0.000 description 1
- 125000003368 amide group Chemical group 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
- 229940048864 ceramide 1 Drugs 0.000 description 1
- 229930183167 cerebroside Natural products 0.000 description 1
- 150000001784 cerebrosides Chemical class 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 229940107200 chondroitin sulfates Drugs 0.000 description 1
- 239000002734 clay mineral Substances 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- OGQYPPBGSLZBEG-UHFFFAOYSA-N dimethyl(dioctadecyl)azanium Chemical compound CCCCCCCCCCCCCCCCCC[N+](C)(C)CCCCCCCCCCCCCCCCCC OGQYPPBGSLZBEG-UHFFFAOYSA-N 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000009881 electrostatic interaction Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 150000002270 gangliosides Chemical class 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000003349 gelling agent Substances 0.000 description 1
- 238000012812 general test Methods 0.000 description 1
- 125000003976 glyceryl group Chemical group [H]C([*])([H])C(O[H])([H])C(O[H])([H])[H] 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 150000002339 glycosphingolipids Chemical class 0.000 description 1
- 239000008269 hand cream Substances 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- IAJILQKETJEXLJ-LECHCGJUSA-N iduronic acid Chemical compound O=C[C@@H](O)[C@H](O)[C@@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-LECHCGJUSA-N 0.000 description 1
- 239000000865 liniment Substances 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 150000004668 long chain fatty acids Chemical class 0.000 description 1
- 238000000691 measurement method Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 125000002811 oleoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])/C([H])=C([H])\C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical group CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 1
- 229920000570 polyether Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 229920002503 polyoxyethylene-polyoxypropylene Polymers 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 239000012488 sample solution Substances 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 229940057429 sorbitan isostearate Drugs 0.000 description 1
- WWUZIQQURGPMPG-KRWOKUGFSA-N sphingosine Chemical compound CCCCCCCCCCCCC\C=C\[C@@H](O)[C@@H](N)CO WWUZIQQURGPMPG-KRWOKUGFSA-N 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/39—Derivatives containing from 2 to 10 oxyalkylene groups
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/68—Sphingolipids, e.g. ceramides, cerebrosides, gangliosides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
- A61K8/735—Mucopolysaccharides, e.g. hyaluronic acid; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/84—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions otherwise than those involving only carbon-carbon unsaturated bonds
- A61K8/86—Polyethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/20—Chemical, physico-chemical or functional or structural properties of the composition as a whole
- A61K2800/26—Optical properties
- A61K2800/262—Transparent; Translucent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
- A61K2800/805—Corresponding aspects not provided for by any of codes A61K2800/81 - A61K2800/95
Definitions
- the present invention relates to a composition stably containing ceramides, and more particularly to a composition containing ceramides and a uronic acid-containing polysaccharide in a specific aqueous solvent.
- JP 2009-269882 A Japanese translation of PCT publication No. 2013-526620 Japanese Patent Application Laid-Open No. 2001-316217
- the present invention has been made in view of the above circumstances, and an object thereof is to provide a composition that suppresses the precipitation of ceramide crystals and provides an excellent effect of improving the barrier function of the stratum corneum.
- the present inventors have found that by containing ceramides and uronic acid-containing polysaccharides in a specific aqueous solvent, crystal precipitation of ceramides is suppressed and , found that when applied to the skin, it rapidly permeates into the stratum corneum, resulting in an excellent effect of improving the barrier function of the stratum corneum, leading to the completion of the present invention.
- the present invention is a composition containing ceramides and uronic acid-containing polysaccharides in an aqueous solvent containing propylene glycol and/or polypropylene glycol.
- composition of the present invention can suppress the precipitation of crystals of ceramides and obtain an excellent effect of improving the barrier function of the stratum corneum due to ceramides.
- Example 1 is an optical micrograph of the composition of Example 1-1.
- 1 is an optical micrograph of the composition of Example 1-2.
- 1 is an optical micrograph of the composition of Comparative Example 1-1.
- the ceramides used in the present invention contain one or more long-chain straight and/or branched alkyl or alkenyl groups, at least two hydroxyl groups, one or more amide groups (and/or amino groups) in the molecule. group), or a derivative in which a phosphatidylcholine residue or a sugar residue is bound to the hydroxyl group of the nonionic amphiphile, and even if it is a natural extract, It may be synthetic.
- sphingosine, phytosphingosine and natural ceramides such as ceramide 1, ceramide 2, ceramide 3, ceramide 4, ceramide 5 and ceramide 6 which are long-chain fatty acid amides thereof; sphingomyelin which is a phospholipid derivative of sphingosine and phytosphingosine , sphingophospholipids such as phytosphingomyelin; sphingoglycolipids and glycosphingolipids such as cerebrosides and gangliosides, which are glycosides thereof; .
- natural ceramides are preferable, and ceramide 2 and ceramide 3 are particularly preferable from the viewpoint of suppressing crystal precipitation.
- ceramides Commercially available products of natural ceramides include, for example, Ceramide I, Ceramide III, Ceramide VI (manufactured by EVONIC), Ceramide TIC-001 (manufactured by Takasago International Corporation), CERAMIDE 2 (manufactured by Croda Japan), Ceracare AC45 ( manufactured by NFC Corporation) and the like.
- the content of ceramides in the composition of the present invention is not particularly limited, it is preferably in the range of 0.001 to 3% by mass (hereinafter simply referred to as "%") from the viewpoint of feel and the like. A range of 0.001 to 1% is more preferred, and a range of 0.01 to 0.5% is even more preferred.
- the uronic acid-containing polysaccharide used in the present invention is a polysaccharide containing at least 10% or more uronic acid in its structure.
- the uronic acid constituting the uronic acid-containing polysaccharide includes glucuronic acid, galacturonic acid, iduronic acid, etc. Among them, those containing glucuronic acid are preferable from the viewpoint of preventing crystallization of ceramides.
- glucuronic acid-containing polysaccharides include chondroitin sulfates, mucopolysaccharides (glycosaminoglycans) such as hyaluronic acids, white fungus polysaccharides, and the like.
- Tremoist TP, SL, and SLB are commercially available as Tremoist TP, SL, and SLB (Nippon Fine Chemical Co., Ltd.).
- hyaluronic acids are preferred.
- hyaluronic acids include hyaluronic acid, derivatives thereof, and salts thereof, and may be derived from natural products (extraction), fermented products, and the like.
- the hyaluronic acid is not particularly limited, but preferably dissolves or disperses in water.
- Examples include sodium hyaluronate, potassium hyaluronate, sodium acetylated hyaluronate, sodium oleoyl hyaluronate, and sodium caproyl hyaluronate. , sodium carboxymethyl hyaluronate, polyethylene glycol hyaluronate, crosslinked sodium hyaluronate, hydroxypropyltrimonium-modified sodium hyaluronate, and the like, and one or more of these can be used.
- the molecular weight of the hyaluronic acid is not particularly limited, but from the viewpoint of preventing crystal precipitation of ceramides, etc., the weight average molecular weight is preferably 300,000 or less, more preferably 1000 to 200,000.
- the weight average molecular weight of hyaluronic acids means a value measured by the following method.
- the weight average molecular weight of the hyaluronic acid used in the present invention is obtained by using hyaluronic acid with a known weight average molecular weight as a standard product, subjecting the sample and standard product to high performance liquid chromatography, and determining the weight average molecular weight and retention time of the standard product from the standard curve.
- the weight average molecular weight of the standard product is determined by measuring the intrinsic viscosity according to the 13th revision of the Japanese Pharmacopoeia: General Test Methods, Section 36 Viscosity Measurement Method, and the formula of Laurent et al. 1960)).
- the content of the uronic acid-containing polysaccharide in the composition of the present invention is not particularly limited, it is preferably in the range of 0.001 to 5%, and 0.01 to 3% from the viewpoint of preventing crystallization of ceramides. A range of % is more preferred, and a range of 0.01 to 1% is even more preferred.
- the content mass ratio of ceramides and uronic acid-containing polysaccharides (ceramides/uronic acid-containing polysaccharides) in the composition of the present invention is not particularly limited, but from the viewpoint of preventing crystallization of ceramides, etc., It is preferably 0.001 to 1, more preferably 0.005 to 0.5.
- aqueous solvent means a solvent composed of water and an aqueous component other than water.
- aqueous component lower alcohols such as ethanol and 2-propanol; polyhydric alcohols such as ethylene glycol, glycerin, 1,3-butylene glycol and propylene glycol; polyethers such as polyethylene glycol and polypropylene glycol; can be used alone or in combination of two or more.
- the composition of the present invention contains propylene glycol and/or polypropylene glycol among these in the aqueous solvent.
- the polypropylene glycol refers to a polymer of propylene glycol, and in the present invention, the degree of polymerization is not particularly limited as long as it is 2 or more, preferably 2 to 9, more preferably 2 to 7. be.
- Polypropylene glycol preferably has a molecular weight of 400 or less, more preferably 200 or less, from the viewpoint of preventing crystallization of ceramides. Examples of such polypropylene glycol having a molecular weight of 200 or less include dipropylene glycol and tripropylene glycol.
- the total content of propylene glycol and polypropylene glycol in the entire aqueous solvent is preferably 30% or more, more preferably 50% or more, and still more preferably 60% or more.
- the content of the entire aqueous solvent in the composition of the present invention is not particularly limited, but is preferably 40 to 99.9%, more preferably 60 to 99%.
- the content of propylene glycol and/or polypropylene glycol in the composition is not particularly limited, it is preferably 30 to 90%, more preferably 50 to 80%, from the viewpoint of preventing crystallization of ceramides.
- the content of water in the composition is preferably 10 to 70%, more preferably 20 to 50%, and the content of water in the aqueous solvent is preferably 5 to 70%. It is more preferably 10 to 50%, more preferably 10 to 40%.
- the content mass ratio of propylene glycol and/or polypropylene glycol and water in the composition ((propylene glycol and/or polypropylene glycol)/water) is 0.1 to 5. It is preferably 0.4 to 4, more preferably 1 to 4.
- composition of the present invention is not particularly limited as long as it contains ceramides and uronic acid-containing polysaccharides in an aqueous solvent, but preferably ceramides and uronic acid-containing polysaccharides ceramides and uronic acid It includes a complex composed of polysaccharide-containing polysaccharides (hereinafter referred to as "ceramides-uronic acid-containing polysaccharide complex"). It is considered that this ceramides-uronic acid-containing polysaccharide complex is formed by electrostatic interaction in an aqueous solvent and maintains a relaxed binding state.
- ceramides in a dissolved state when applied to the skin, it quickly permeates the stratum corneum, and an excellent effect of improving the barrier function of the stratum corneum can be obtained.
- the ceramides-uronic acid-containing polysaccharide complex When the ceramides-uronic acid-containing polysaccharide complex is formed, it floats in the composition as haze-like or fibrous amorphous aggregates, resulting in a cloudy state. The presence or absence of the ceramides-uronic acid-containing polysaccharide complex can be confirmed by observing the appearance (see FIGS. 1 and 2).
- the complex is observed as an amorphous aggregate by optical microscope observation (bright field image) under the conditions described in Examples, it can also be confirmed by the presence or absence of such amorphous aggregates. .
- the ceramides form a complex with the uronic acid-containing polysaccharide, so that the ceramides crystals do not precipitate and are stably present in the composition.
- the composition was placed in a glass container, sealed, and stored at constant temperatures of 50 ° C. and 5 ° C. for 2 weeks, and then observed with an optical microscope at either storage temperature.
- FIGS. 1 and 2 show that the presence of crystals derived from ceramides is not observed (see FIGS. 1 and 2).
- the bright-field images shown in FIGS. 1 to 3 were observed by a bright-field observation method in which light transmitted or reflected by the sample was observed, and the polarized-field images were observed by a polarized-field observation method in which observation was performed under crossed Nicols. It is what I did. Presence or absence of precipitation of ceramide crystals can be confirmed by the contrast of light and dark in the polarized field image (see FIG. 3).
- composition of the present invention can be made into a transparent composition by further using a nonionic surfactant having an isostearic acid skeleton.
- a nonionic surfactant having an isostearic acid skeleton In this composition, no amorphous aggregates were observed by visual observation, but amorphous aggregates were observed by optical microscope observation. Existence can be confirmed.
- the nonionic surfactant having an isostearic acid skeleton is not particularly limited as long as it dissolves or disperses in water.
- Acid polyoxyethylene glyceryl, polyglyceryl isostearate, polyglyceryl diisostearate, polyoxyethylene glyceryl isostearate, polyoxyethylene hydrogenated castor oil isostearate, polyoxyethylene sorbitan isostearate, polyoxyethylene glycol isostearate, isostearoyl polyethylene glycol, etc. is mentioned.
- the nonionic surfactant having an isostearic acid skeleton includes polyoxyethylene glyceryl isostearate, polyglyceryl isostearate, polyglyceryl diisostearate, and polyoxyethylene isostearate from the viewpoint of preventing crystallization of ceramides.
- Hydrogenated castor oil is preferred, and polyoxyethylene isostearate (8) glycerin, polyglycerol diisostearate (10), and polyoxyethylene isostearate hydrogenated castor oil are more preferred.
- GWIS-108 EMALEC RWIS-150 (manufactured by Nihon Emulsion Co., Ltd.), Nikkor Decagrin 2-ISV (manufactured by Nippon Surfactant Co., Ltd.), and the like. These 1 type(s) or 2 or more types can be used.
- the content of the nonionic surfactant having an isostearic acid skeleton in the composition of the present invention is not particularly limited, but from the viewpoint of the dispersibility of the ceramides-uronic acid-containing polysaccharide complex, it is 0.01 to 10%. is preferred, 0.05 to 5% is more preferred, and 0.1 to 2% is even more preferred.
- the content mass ratio of the ceramides and the nonionic surfactant having an isostearic acid skeleton in the composition is not particularly limited, but ceramides-uronic acid-containing From the viewpoint of dispersibility of the polysaccharide complex, it is preferably 0.001 to 1, more preferably 0.001 to 0.1, even more preferably 0.001 to 0.05.
- nonionic surfactant having an isostearic acid skeleton
- further nonionic surfactants and / or anions It is preferred to use a type surfactant.
- Nonionic surfactants are not particularly limited, but the HLB of the nonionic surfactant is preferably 10 to 18. , 10-16.
- These nonionic surfactants include, for example, sorbitan fatty acid esters, polyglycerol fatty acid esters, sucrose fatty acid esters, polyoxyethylene sorbitan fatty acid esters, polyoxyethylene sorbit fatty acid esters, polyoxyethylene glycol fatty acid esters, polyoxyethylene Glycerin fatty acid ester, polyoxyethylene alkyl ether, polyoxyethylene cholesteryl ether, polyoxyethylene phytosteryl ether, polyoxyethylene polyoxypropylene alkyl ether, polyoxyethylene hydrogenated castor oil, polyoxyethylene fatty acid ethanolamide, polyoxyalkylene modification Silicones, polyoxyalkylene alkyl co-modified silicones and the like can be mentioned.
- sucrose fatty acid esters, polyoxyethylene hydrogenated castor oil, and polyoxyethylene cholesteryl ether are more preferable, and commercially available products include Nikkor HCO-60 (manufactured by Nippon Surfactant Co., Ltd.) and EMALEX CS-10 ( Nippon Emulsion Co., Ltd.), DK Ester S-160 (Daiichi Kogyo Seiyaku Co., Ltd.), and the like. One or more of these can be appropriately selected and used.
- HLB Hydrophilicity-lipophilicity Balance
- HLB "inorganic value (IV)/organic value (OV)” x 10 (Formula 1) (See Yoshio Koda, “Organic Conceptual Diagram-Basics and Applications-", pp. 11-17, Sankyo Publishing, 1984).
- anionic surfactants include stearic acid, lauric acid, fatty acid salts such as isostearic acid, alkylsulfonates, ⁇ -olefinsulfonates, N-long-chain acyl amino acid salts, N-acyl taurates, N -alkyl-N-acyl taurine salts, polyoxyethylene alkyl ether sulfates, polyoxyethylene alkylphenyl ether sulfates, N-acyl amino acid salts, N-acyl-N-alkyl amino acid salts, etc., particularly fatty acid salts, N-alkyl-N-acyl taurate and N-acyl taurate are preferred, and isostearate and/or stearoylmethyl taurate are more preferred.
- fatty acid salts such as isostearic acid, alkylsulfonates, ⁇ -olefinsulfonates, N-long-chain acyl amino acid salts, N-acyl taurates, N
- These salts include Na, K, Ca, Al, Mg, Zn and triethanolamine salts, more preferably Na, K and triethanolamine salts.
- Commercially available products include isostearic acid EX (manufactured by Kokyu Alcohol Kogyo Co., Ltd.), Nikkor SMT (manufactured by Nippon Surfactant Co., Ltd.), and the like, and one or more of these can be appropriately selected and used.
- nonionic surfactants excluding nonionic surfactants having an isostearic acid skeleton
- anionic surfactants is not particularly limited, but ceramides-uronic acid-containing From the viewpoint of dispersibility of the saccharide complex, the content is preferably 0.05 to 10%, more preferably 0.1 to 5%, and even more preferably 0.15 to 4.5%. .
- the content mass ratio of a nonionic surfactant having an isostearic acid skeleton to a nonionic surfactant (excluding a nonionic surfactant having an isostearic acid skeleton) and/or an anionic surfactant is not particularly limited, but , From the viewpoint of the dispersibility of the ceramides-uronic acid-containing polysaccharide complex, it is preferably 0.05 to 3, more preferably 0.1 to 2, and further preferably 0.2 to 1. preferable.
- the method for producing the composition of the present invention is not particularly limited, for example, a ceramides solution in which ceramides are dissolved and a uronic acid-containing polysaccharide solution in which uronic acid-containing polysaccharides are dissolved are heated and mixed.
- a ceramides solution in which ceramides are dissolved and a uronic acid-containing polysaccharide solution in which uronic acid-containing polysaccharides are dissolved are heated and mixed.
- the aqueous components constituting the aqueous solvent it is preferable to use propylene glycol and/or polypropylene glycol in the ceramides solution from the viewpoint of suppressing crystal precipitation of ceramides.
- the content of propylene glycol and/or polypropylene glycol in the solvent used for the ceramides solution is not particularly limited, but is preferably 60% or more, more preferably 80% or more.
- a solution of ceramides can be prepared by heating and dissolving ceramide
- water is preferably used for the uronic acid-containing polysaccharide solution.
- the water content in the solvent used for the uronic acid-containing polysaccharide solution is not particularly limited, but is preferably 50 to 99%, more preferably 70 to 99%.
- a uronic acid-containing polysaccharide solution can be prepared by dissolving the uronic acid-containing polysaccharide in such a solvent.
- the uronic acid-containing polysaccharide does not require any particular heating operation and can be dissolved at room temperature (25° C.), but from the viewpoint of suppressing the precipitation of ceramide crystals, it is preferable to heat and dissolve.
- the heating temperature is preferably 70 to 100°C, more preferably 80 to 100°C.
- the composition of the present invention can be obtained. It is preferable because it can be obtained suitably. From the viewpoint of suppressing crystal precipitation of ceramides, it is preferable to mix the ceramides solution and the uronic acid-containing polysaccharide solution under a temperature condition of 70 to 100°C.
- composition of the present invention obtained as described above can be used as a cosmetic or external skin preparation as it is, or can be combined with other ingredients to make a cosmetic or external skin preparation.
- skin care cosmetics such as lotion, milky lotion, cream, eye cream, serum, massage agent, pack, hand cream, body lotion, and body cream
- cosmetics such as base cosmetics for makeup, external liquids, external gels
- Skin external preparations such as agents, creams, ointments, liniments, lotions, poultices, plasters, sprays, and aerosols can be exemplified.
- the content of the composition in the cosmetic or topical skin preparation is not particularly limited, but is preferably 1 to 50%, more preferably 5 to 20%, in the cosmetic or topical skin preparation.
- the dosage form is also not particularly limited, and various dosage forms such as aqueous cosmetics, water-in-oil cosmetics, oil-in-water cosmetics, and oily cosmetics can be taken.
- various dosage forms such as aqueous cosmetics, water-in-oil cosmetics, oil-in-water cosmetics, and oily cosmetics can be taken.
- external preparations for skin include quasi-drugs and pharmaceuticals.
- ingredients that are blended in ordinary cosmetics or topical skin preparations can be used as long as they do not interfere with the effects of the present invention and the formation of complexes.
- optional components include oils, alcohols, powders, water-soluble polymers, film-forming agents, surfactants, oil-soluble gelling agents, organically modified clay minerals, resins, ultraviolet absorbers, Preservatives, antibacterial agents, fragrances, antioxidants, pH adjusters, chelating agents, skin active ingredients, and the like can be mentioned.
- aqueous cosmetic can be mentioned as a suitable dosage form for the cosmetic of the present invention.
- aqueous cosmetic preparation means a dosage form in which a water phase composed of an aqueous solvent is used as a continuous phase and substantially no oily component is contained.
- substantially free of oily components means that the content of oily components in the cosmetic is preferably less than 0.5%, more preferably less than 0.1%, and still more preferably 0.05%. means less than It is preferable that the water-based cosmetic contains a nonionic surfactant having an isostearic acid skeleton, because the transparency is improved and the effect of suppressing crystallization of ceramides is enhanced.
- the nonionic surfactant having an isostearic acid skeleton may be contained in the composition, or may be added separately from the composition to prepare a cosmetic or topical skin preparation.
- the content of the nonionic surfactant having an isostearic acid skeleton in the aqueous cosmetic is not particularly limited, but is preferably 0.01 to 10% from the viewpoint of the dispersibility of the ceramides-uronic acid-containing polysaccharide complex. It is preferably 0.05 to 5%, more preferably 0.1 to 2%.
- the content mass ratio of the ceramides and the nonionic surfactant having an isostearic acid skeleton in the aqueous cosmetic is not particularly limited, but ceramides-uronic acid It is preferably 0.001 to 1, more preferably 0.001 to 0.1, even more preferably 0.001 to 0.05, from the viewpoint of dispersibility of the contained polysaccharide complex.
- the cosmetic or topical skin preparation of the present invention was subjected to the aging stability test described in the Examples, sealed in a glass container, stored at constant temperatures of 50 ° C. and 5 ° C. for 2 weeks, respectively, and then stored at either storage temperature. Also, the presence of crystals derived from ceramides is not observed by optical microscope observation (see FIG. 3). Whether or not the ceramides and the uronic acid-containing polysaccharide form a complex can be determined based on the presence or absence of crystal precipitation in the stability test over time.
- composition (1) Preparation of composition (1): Examples 1-1 to 1-3, Comparison 1-1 A composition was prepared according to the following formulation and manufacturing method. Each obtained composition was evaluated for "complex formation”, “stability immediately after production”, and “stability over time (5°C and 50°C/2 weeks)" according to the following methods and criteria. Table 1 shows the results. ⁇ Example 1-1> A composition was prepared according to the following formulation and manufacturing method.
- Example 1-2 (Prescription) [% by mass] (1) Ceramide 2 *4 0.01 (2) Dipropylene glycol *2 49.99 (3) sodium hyaluronate *3 1.0 (4) Dipropylene glycol *2 19.0 (5) Water remaining amount * 4 Ceramide TIC-001 (manufactured by Takasago International Corporation) (Manufacturing method) (1) to (2) and (3) to (5) were mixed and dissolved by heating at 80°C. Both were mixed and stirred at 80° C. for 10 minutes using a hotting stirrer SMH-18 (manufactured by Masuda Rika Kogyo Co., Ltd.), and then cooled to room temperature to prepare a composition.
- a hotting stirrer SMH-18 manufactured by Masuda Rika Kogyo Co., Ltd.
- Example 1-3 (Prescription) [% by mass] (1) Ceramide 2 *4 0.01 (2) Tripropylene glycol *5 49.99 (3) Acetylated sodium hyaluronate *6 0.1 (4) Tripropylene glycol *5 19.0 (5) Water remaining amount * 5 TPG-H (manufactured by ADEKA) *6 Acetylated sodium hyaluronate (manufactured by Shiseido) (Manufacturing method) (1) to (2) and (3) to (5) were mixed and dissolved by heating at 80°C. Both were mixed and stirred at 80° C. for 10 minutes using a hotting stirrer SMH-18 (manufactured by Masuda Rika Kogyo Co., Ltd.), and then cooled to room temperature to prepare a composition.
- SMH-18 hotting stirrer
- composition (2) Examples 1-4 to 1-15, Comparison 1-2 Compositions were prepared according to the formulations and production methods shown in Tables 2 and 3 below. Each obtained composition was evaluated for "formation of complex”, “stability immediately after production”, and “stability over time (5°C and 50°C/2 weeks)" according to the above methods and criteria. The results are shown in Tables 2-3.
- Manufacturing method (1) to (2) and (7) to (9) were mixed and dissolved by heating at 80°C, and (3) to (6) and (10) were mixed and dissolved by heating at 80°C. Both were mixed and stirred at 80° C. for 10 minutes using a hotting stirrer SMH-18 (manufactured by Masuda Rika Kogyo Co., Ltd.), and then cooled to room temperature to prepare a composition.
- aqueous cosmetics were prepared according to the following formulation and production method, and the "complex formation” and "stability immediately after production” were determined according to the same method and criteria as above. and “stability over time” were evaluated.
- the dispersibility of the formed ceramide-hyaluronic acid complex the following methods and criteria were used for "stability immediately after production”, “production stability (5°C/2 weeks)", and “production stability (50°C/2 weeks)”. 2 weeks)” was evaluated. Results are shown in Tables 4 and 5.
- Example 1-1 composition 10.0
- Polyoxyethylene hydrogenated castor oil isostearate *10 0.5
- Dipropylene glycol *2 5.0 1,3-butylene glycol *11 10.0 (6)
- Water remaining amount * 9 Nikkor Decagrin 2-ISV (manufactured by Nippon Surfactant Co., Ltd.) * 10 EMALEX RWIS-150 (manufactured by Nippon Emulsion Co., Ltd.) *11 1,3-butylene glycol (manufactured by Daicel) (Manufacturing method)
- After mixing (1) and (2) to (6) respectively by heating to 80 ° C. both are mixed and stirred at 80 ° C. for 10 minutes using a hot stirring stirrer SMH-18 (manufactured by Masuda Rika Kogyo Co., Ltd.). was prepared by cooling to room temperature.
- Example 2-2 [% by mass] (1)
- Example 1-2 composition 10.0 Polyoxyethylene (10) Cholesteryl ether *12 0.15 (3) Polyoxyethylene isostearate (8) Glycerin *13 0.1 (4) Dipropylene glycol *2 5.0 (5) 1,3-butylene glycol *11 10.0 (6) Remaining amount of water * 12 EMALEX CS-10 (manufactured by Nippon Emulsion Co., Ltd.) *13 EMALEX GWIS-108 (manufactured by Nihon Emulsion Co., Ltd.) (Manufacturing method) After mixing (1) and (2) to (6) respectively by heating to 80 ° C., both are mixed and stirred at 80 ° C. for 10 minutes using a hot stirring stirrer SMH-18 (manufactured by Masuda Rika Kogyo Co., Ltd.). was prepared by cooling to room temperature.
- SMH-18 hot stirring stirrer
- Example 2-3 [% by mass] (1)
- Example 1-3 composition 10.0 Polyglycerol diisostearate (10) *9 0.05 (3) Isostearic acid *14 0.15 (4) Triethanolamine *15 0.08 (5) 1,3-butylene glycol *11 13.0 (6) Water remaining amount * 14 Isostearic acid EX (manufactured by Kokyu Alcohol Kogyo Co., Ltd.) *15 TRIETHANOLAMINE CARE (manufactured by BASF) (Manufacturing method) After mixing (1) and (2) to (6) respectively by heating to 80 ° C., both are mixed and stirred at 80 ° C. for 10 minutes using a hot stirring stirrer SMH-18 (manufactured by Masuda Rika Kogyo Co., Ltd.). was prepared by cooling to room temperature.
- SMH-18 hot stirring stirrer
- Prescription example 1 transparent lotion> [% by mass] (1) Ceramide 2 *4 0.01 (2) Dipropylene glycol *2 10.0 (3) sodium hyaluronate *3 1.0 (4) Water 10.0 (5) Polyoxyethylene (10) Cholesteryl ether *12 1.5 (6) Polyoxyethylene isostearate (8) Glycerin *13 1.0 (7) Water 10.0 (8) 1,3-butylene glycol *11 10.0 (9) Remaining amount of water (manufacturing method) (1) to (2), (3) to (4), and (5) to (9) are mixed and dissolved at 80°C. T. K.
- (3) to (4) are added to (1) to (2) and mixed for 10 minutes.
- (5) to (9) were added thereto, mixed for 10 minutes, and then cooled to room temperature to prepare.
- (3) to (4) are added to (1) to (2) and mixed for 10 minutes.
- (5) to (9) were added thereto, mixed for 10 minutes, and then cooled to room temperature to prepare.
- composition of the present invention contains ceramides that tend to precipitate as crystals, and by containing ceramides and uronic acid-containing polysaccharides in a specific aqueous solvent, the precipitation of crystals is suppressed, and ceramides It is possible to obtain an excellent stratum corneum barrier effect by Therefore, it can be suitably used as a raw material for cosmetics and external preparations for skin.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Birds (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Dermatology (AREA)
- Emergency Medicine (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Cosmetics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
本発明に使用されるヒアルロン酸類の重量平均分子量は、重量平均分子量既知のヒアルロン酸を標準品として用い、試料と標準品を高速液体クロマトグラフィーにかけ、標準品の重量平均分子量とリテンションタイムから標準曲線を求め、試料溶液のリテンションタイムに相当する重量平均分子量により求めることができる。なお、標準品の重量平均分子量は、第十三改正日本薬局方:一般試験法・第36項粘度測定法に従って極限粘度を測定し、Laurentらの式(Biochim.Biophys.Acta、42、476(1960))によって算出することができる。
HLB=「無機性値(IV)/有機性値(OV)」×10・・・(式1)
(甲田善生著、「有機概念図-基礎と応用-」、11~17頁、三共出版、1984年発行参照)。
以下の処方、製法により組成物を調製した。得られた各組成物について下記の方法・基準により「複合体の形成」、「製造直後の安定性」、「経時安定性(5℃及び50℃/2週間)」について評価した。結果を表1に示す。
<実施例1-1>
以下の処方、製法により組成物を調製した。
(処方) [質量%]
(1)セラミド3*1 0.1
(2)ジプロピレングリコール*2 49.9
(3)ヒアルロン酸ナトリウム*3 1.0
(4)ジプロピレングリコール*2 19.0
(5)水 残量
*1 CERAMIDE3(EVONIC社製)
*2 DPG-RF(ADEKA社製)
*3 ヒアルロン酸FCH-SU(重量平均分子量10万 フードケミファ社製)
(製法)
(1)~(2)、(3)~(5)をそれぞれ80℃にて加熱混合溶解した。両者を混合し、ホッティングスターラー SMH-18(増田理化工業社製)用いて80℃にて10分間攪拌した後に、室温まで冷却し組成物を調製した。
(処方) [質量%]
(1)セラミド2*4 0.01
(2)ジプロピレングリコール*2 49.99
(3)ヒアルロン酸ナトリウム*3 1.0
(4)ジプロピレングリコール*2 19.0
(5)水 残量
*4 セラミドTIC-001(高砂香料社製)
(製法)
(1)~(2)、(3)~(5)をそれぞれ80℃にて加熱混合溶解した。両者を混合し、ホッティングスターラー SMH-18(増田理化工業社製)用いて80℃にて10分間攪拌した後に、室温まで冷却し組成物を調製した。
(処方) [質量%]
(1)セラミド2*4 0.01
(2)トリプロピレングリコール*5 49.99
(3)アセチル化ヒアルロン酸ナトリウム*6 0.1
(4)トリプロピレングリコール*5 19.0
(5)水 残量
*5 TPG-H(ADEKA社製)
*6 アセチル化ヒアルロン酸ナトリウム(資生堂社製)
(製法)
(1)~(2)、(3)~(5)をそれぞれ80℃にて加熱混合溶解した。両者を混合し、ホッティングスターラー SMH-18(増田理化工業社製)用いて80℃にて10分間攪拌した後に、室温まで冷却し組成物を調製した。
(処方) [質量%]
(1)セラミド3*1 0.1
(2)ヒアルロン酸ナトリウム*3 1.0
(3)水 残量
(製法)
(2)~(3)を加熱混合溶解した後に、(1)を添加し、ホッティングスターラー SMH-18(増田理化工業社製)用いて80℃にて10分間攪拌した後に、室温まで冷却し調製した。
製造したセラミド‐ヒアルロン酸複合体の形成及びセラミド由来の結晶の有無に関しては、光学顕微鏡(オリンパス社製 BX-51、400倍率)観察にて以下の基準により確認した。結果を表1に示す。また実施例1-1,1-2、比較例1-1の顕微鏡写真を図1~3に示す。
1.複合体の形成
製造直後の組成物において、以下の基準により確認した。
○:不定形凝集物あり
×:不定形凝集物なし
2.製造直後の安定性(セラミド類由来結晶の有無)
製造直後の組成物において、以下の基準により確認した。
○:セラミド類由来結晶なし
×:セラミド類由来結晶あり
3.経時安定性(セラミド類由来結晶の有無)
50℃及び5℃の恒温下でそれぞれ2週間保管後のセラミド類由来の結晶の有無について、以下の基準で評価した。
○:セラミド類由来結晶なし
×:セラミド類由来結晶あり
下記表2~3の処方及び製法により組成物を調製した。得られた各組成物について上記の方法・基準により、「複合体の形成」、「製造直後の安定性」、「経時安定性(5℃及び50℃/2週間)」について評価した。結果を表2~3に示す。
(製法)
(1)~(2)と(7)~(9)を80℃で加熱混合溶解し、(3)~(6)と(10)を80℃で加熱混合溶解した。両者を混合し、ホッティングスターラー SMH-18(増田理化工業社製)用いて80℃にて10分間攪拌した後に、室温まで冷却し組成物を調製した。
実施例1-1~1-3において調製した組成物を用いて、下記処方及び製法により水性化粧料を調製し、上記と同様の方法・基準により「複合体の形成」、「製造直後の安定性」、「経時安定性」について評価した。また形成されたセラミド-ヒアルロン酸複合体の分散性について、以下の方法・基準により「製造直後の安定性」、「製造安定性(5℃/2週間)」、「製造安定性(50℃/2週間)」を評価した。結果を表4及び5に示す。
(処方) [質量%]
(1)実施例1-1組成物 10.0
(2)ジイソステアリン酸ポリグリセリン(10)*9 0.1
(3)イソステアリン酸ポリオキシエチレン水添ヒマシ油*10 0.5
(4)ジプロピレングリコール*2 5.0
(5)1,3-ブチレングリコール*11 10.0
(6)水 残量
*9 ニッコール デカグリン 2-ISV(日本サーファクタント社製)
*10 EMALEX RWIS-150(日本エマルション社製)
*11 1,3-ブチレングリコール(ダイセル社製)
(製法)
(1)、(2)~(6)をそれぞれ80℃に加熱混合した後に、両者を混合し、ホッティングスターラー SMH-18(増田理化工業社製)用いて80℃にて10分間攪拌した後に、室温まで冷却し調製した。
(処方) [質量%]
(1)実施例1-2組成物 10.0
(2)ポリオキシエチレン(10)コレステリルエーテル*12 0.15
(3)イソステアリン酸ポリオキシエチレン(8)グリセリン*13 0.1
(4)ジプロピレングリコール*2 5.0
(5)1,3-ブチレングリコール*11 10.0
(6)水 残量
*12 EMALEX CS-10(日本エマルション社製)
*13 EMALEX GWIS-108(日本エマルション社製)
(製法)
(1)、(2)~(6)をそれぞれ80℃に加熱混合した後に、両者を混合し、ホッティングスターラー SMH-18(増田理化工業社製)用いて80℃にて10分間攪拌した後に、室温まで冷却し調製した。
(処方) [質量%]
(1)実施例1-3組成物 10.0
(2)ジイソステアリン酸ポリグリセリン(10)*9 0.05
(3)イソステアリン酸 *14 0.15
(4)トリエタノールアミン*15 0.08
(5)1,3-ブチレングリコール*11 13.0
(6)水 残量
*14 イソステアリン酸EX(高級アルコール工業社製)
*15 TRIETHANOLAMINE CARE(BASF社製)
(製法)
(1)、(2)~(6)をそれぞれ80℃に加熱混合した後に、両者を混合し、ホッティングスターラー SMH-18(増田理化工業社製)用いて80℃にて10分間攪拌した後に、室温まで冷却し調製した。
目視によるセラミド-ヒアルロン酸複合体の沈降の有無を確認することで、評価を行った。具体的には、製造直後の複合体の分散状態と、50℃及び5℃の恒温下で2週間保管後の分散状態を以下の基準で評価した。結果を下記表に示す。
○:沈降が認められない
△:わずかに沈降が認められる
×:沈降が認められる
下記表6の処方及び下記製法により水性化粧料を調製した。得られた水性化粧料について上記の方法・基準と同様にして「複合体の形成」、「製造直後の安定性」、「経時安定性」、「製造直後の安定性」、「製造安定性(5℃/2週間)」、「製造安定性(50℃/2週間)」について評価した。結果を表6に併せて示す。
(製法)
実施例2-4~2-11:
A:(1)と(3)、(2)と(4)の30部分、(4)の残量部と(5)~(12)をそれぞれ80℃にて混合溶解する。
B:T.K.HOMO DISPER(特殊機化工業社製)を用い、Aで調整した(1)と(3)に(2)と(4)の30部分を添加し10分間混合する。
C:BにAで調整した(5)~(12)を添加し10分間混合した後に、室温まで冷却し調製した。
比較例2-1:
D:(1)と(3)、(4)~(12)をそれぞれ80℃にて混合溶解する。
E:T.K.HOMO DISPER(特殊機化工業社製)を用い、Dで調整した(1)と(3)に(4)~(12)を添加し10分間混合した後に、室温まで冷却し調製した。
(処方) [質量%]
(1)セラミド2*4 0.01
(2)ジプロピレングリコール*2 10.0
(3)ヒアルロン酸ナトリウム*3 1.0
(4)水 10.0
(5)ポリオキシエチレン(10)コレステリルエーテル*12 1.5
(6)イソステアリン酸ポリオキシエチレン(8)グリセリン*13 1.0
(7)水 10.0
(8)1,3-ブチレングリコール*11 10.0
(9)水 残量
(製法)
(1)~(2)、(3)~(4)、(5)~(9)をそれぞれ80℃にて混合溶解する。
T.K.HOMO DISPER(特殊機化工業社製)を用い、(1)~(2)に(3)~(4)を添加し10分間混合する。そこに(5)~(9)を添加し10分間混合した後に、室温まで冷却し調製した。
(処方) [質量%]
(1)セラミド3*1 0.001
(2)プロピレングリコール 10.0
(3)アセチル化ヒアルロン酸ナトリウム*6 0.1
(4)水 10.0
(5)ジイソステアリン酸ポリグリセリン(10)*9 0.1
(6)イソステアリン酸*14 0.3
(7)トリエタノールアミン*15 0.15
(8)1,3-ブチレングリコール*11 5.0
(9)水 残量
(製法)
(1)~(2)、(3)~(4)、(5)~(9)をそれぞれ80℃にて混合溶解する。
T.K.HOMO DISPER(特殊機化工業社製)を用い、(1)~(2)に(3)~(4)を添加し10分間混合する。そこに(5)~(9)を添加し10分間混合した後に、室温まで冷却し調製した。
<処方例3 シワ改善透明美容液>
(1)セラミド2*4 0.05
(2)ジプロピレングリコール*2 10.0
(3)ヒアルロン酸ナトリウム*3 1.0
(4)水 残量
(製法)
(1)~(2)、(3)~(4)をそれぞれ80℃にて加熱した後に、両者を混合し、T.K.HOMO DISPER(特殊機化工業社製)を用いて80℃にて10分間攪拌した後に、室温まで冷却し調製した。
Claims (15)
- プロピレングリコール及び/又はポリプロピレングリコールを含有する水性溶媒中に、セラミド類及びウロン酸含有多糖類を含有する組成物。
- セラミド類とウロン酸含有多糖類との含有質量比(セラミド類/ウロン酸含有多糖類)が0.001~1である請求項1に記載の組成物。
- セラミド類が、セラミド2及び/又はセラミド3である請求項1又は2に記載の組成物。
- ウロン酸含有多糖類が、グルクロン酸含有多糖類である請求項1~3のいずれかの項記載の組成物。
- グルクロン酸含有多糖類が、ムコ多糖類及び/又はシロキクラゲ多糖類である請求項4記載の組成物。
- ムコ多糖類が、ヒアルロン酸類及び/又はコンドロイチン硫酸ナトリウムである請求項5記載の組成物。
- ヒアルロン酸類が、アセチル化ヒアルロン酸及び/又はヒアルロン酸ナトリウムである請求項6記載の組成物。
- ヒアルロン酸類の重量平均分子量が30万以下である請求項6又は7に記載の組成物。
- セラミド類とウロン酸含有多糖類が複合体を形成するものである請求項1~8のいずれかの項に記載の組成物。
- ポリプロピレングリコールが、ジプロピレングリコール及び/又はトリプロピレングリコールである請求項1~9のいずれかの項記載の組成物。
- 請求項1~10のいずれかの項記載の組成物を含有する化粧料または皮膚外用剤。
- さらに、イソステアリン酸骨格を有する非イオン型界面活性剤を含有する請求項11に記載の化粧料または皮膚外用剤。
- 組成物中のセラミド類とイソステアリン酸骨格を有する非イオン型界面活性剤の含有質量比(セラミド類/イソステアリン酸骨格を有する非イオン型界面活性剤)が0.001~1である請求項12に記載の化粧料または皮膚外用剤。
- 次の工程(1)~(3);
(1)セラミド類を水性溶媒に加熱溶解させてセラミド類溶液を得る工程
(2)ウロン酸含有多糖類を水性溶媒に溶解させてウロン酸含有多糖類溶液を得る工程
(3)(1)で得られたセラミド類溶液と(2)で得られたウロン酸含有多糖類溶液とを混合する工程
を含有することを特徴とするセラミド類及びウロン酸含有多糖類からなる複合体の製造方法。 - セラミド類を水性溶媒に加熱溶解させて得られたセラミド類溶液と、ウロン酸含有多糖類を水性溶媒に溶解させて得られたウロン酸含有多糖類溶液とを混合することによりセラミド類及びウロン酸含有多糖類からなる複合体を形成させることを特徴とするセラミド類の結晶析出抑制方法。
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2022578210A JPWO2022163336A1 (ja) | 2021-01-29 | 2022-01-11 | |
CN202280012429.5A CN116963713A (zh) | 2021-01-29 | 2022-01-11 | 含有神经酰胺类的组合物 |
KR1020237025373A KR20230133305A (ko) | 2021-01-29 | 2022-01-11 | 세라마이드류 함유 조성물 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2021013381 | 2021-01-29 | ||
JP2021-013381 | 2021-01-29 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2022163336A1 true WO2022163336A1 (ja) | 2022-08-04 |
Family
ID=82653255
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2022/000499 WO2022163336A1 (ja) | 2021-01-29 | 2022-01-11 | セラミド類含有組成物 |
Country Status (5)
Country | Link |
---|---|
JP (1) | JPWO2022163336A1 (ja) |
KR (1) | KR20230133305A (ja) |
CN (1) | CN116963713A (ja) |
TW (1) | TW202245734A (ja) |
WO (1) | WO2022163336A1 (ja) |
Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2004161655A (ja) * | 2002-11-12 | 2004-06-10 | Pigeon Corp | セラミド類含有乳化物の製造方法、および乳化物 |
JP2006219432A (ja) * | 2005-02-10 | 2006-08-24 | Yukihiro Hirose | 肌荒れ防止作用を有する組成物および化粧料、飲料 |
JP2008120731A (ja) * | 2006-11-13 | 2008-05-29 | Kose Corp | ベシクル組成物及びそれを配合した皮膚外用剤 |
JP2009269882A (ja) * | 2008-05-09 | 2009-11-19 | Fujifilm Corp | 外用組成物およびその製造方法 |
WO2009139231A1 (ja) * | 2008-05-16 | 2009-11-19 | 株式会社ニチレイバイオサイエンス | ラン科植物から得られる抽出物およびその製造方法、ならびにラン科植物から得られる抽出物を含有する皮膚外用剤 |
JP2011132131A (ja) * | 2009-12-22 | 2011-07-07 | Yukako Sugawara | 化粧液及び化粧液の製造方法 |
JP2012001556A (ja) * | 2011-09-06 | 2012-01-05 | Fujifilm Corp | 外用組成物およびその製造方法 |
JP2019019100A (ja) * | 2017-07-20 | 2019-02-07 | クラシエホームプロダクツ株式会社 | 皮膚化粧料 |
WO2020175700A1 (ja) * | 2019-02-28 | 2020-09-03 | 株式会社日本触媒 | 化粧料用水性分散体、化粧料組成物、及び化粧料の製造方法 |
JP2020164479A (ja) * | 2019-03-29 | 2020-10-08 | 株式会社コーセー | 水中油型乳化化粧料 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP4350269B2 (ja) | 2000-05-11 | 2009-10-21 | 高砂香料工業株式会社 | 化粧料添加用組成物 |
CA2703532C (en) | 2010-05-10 | 2018-05-01 | Eva Turley | Topically administered, skin-penetrating glycosaminoglycan formulations suitable for use in cosmetic and pharmaceutical applications |
-
2022
- 2022-01-11 WO PCT/JP2022/000499 patent/WO2022163336A1/ja active Application Filing
- 2022-01-11 CN CN202280012429.5A patent/CN116963713A/zh active Pending
- 2022-01-11 KR KR1020237025373A patent/KR20230133305A/ko unknown
- 2022-01-11 JP JP2022578210A patent/JPWO2022163336A1/ja active Pending
- 2022-01-20 TW TW111102325A patent/TW202245734A/zh unknown
Patent Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2004161655A (ja) * | 2002-11-12 | 2004-06-10 | Pigeon Corp | セラミド類含有乳化物の製造方法、および乳化物 |
JP2006219432A (ja) * | 2005-02-10 | 2006-08-24 | Yukihiro Hirose | 肌荒れ防止作用を有する組成物および化粧料、飲料 |
JP2008120731A (ja) * | 2006-11-13 | 2008-05-29 | Kose Corp | ベシクル組成物及びそれを配合した皮膚外用剤 |
JP2009269882A (ja) * | 2008-05-09 | 2009-11-19 | Fujifilm Corp | 外用組成物およびその製造方法 |
WO2009139231A1 (ja) * | 2008-05-16 | 2009-11-19 | 株式会社ニチレイバイオサイエンス | ラン科植物から得られる抽出物およびその製造方法、ならびにラン科植物から得られる抽出物を含有する皮膚外用剤 |
JP2011132131A (ja) * | 2009-12-22 | 2011-07-07 | Yukako Sugawara | 化粧液及び化粧液の製造方法 |
JP2012001556A (ja) * | 2011-09-06 | 2012-01-05 | Fujifilm Corp | 外用組成物およびその製造方法 |
JP2019019100A (ja) * | 2017-07-20 | 2019-02-07 | クラシエホームプロダクツ株式会社 | 皮膚化粧料 |
WO2020175700A1 (ja) * | 2019-02-28 | 2020-09-03 | 株式会社日本触媒 | 化粧料用水性分散体、化粧料組成物、及び化粧料の製造方法 |
JP2020164479A (ja) * | 2019-03-29 | 2020-10-08 | 株式会社コーセー | 水中油型乳化化粧料 |
Also Published As
Publication number | Publication date |
---|---|
CN116963713A (zh) | 2023-10-27 |
JPWO2022163336A1 (ja) | 2022-08-04 |
KR20230133305A (ko) | 2023-09-19 |
TW202245734A (zh) | 2022-12-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TWI451877B (zh) | Emulsion composition | |
CN106974848B (zh) | 一种费托蜡液晶化妆品及其制备方法 | |
KR101633639B1 (ko) | 자기회합 겔 특성을 이용한 세포막 유사 구조의 나노 겔타입의 에멀젼 및 그를 이용한 화장료 조성물 | |
JP6057461B2 (ja) | αゲル構造体およびそれを含有する化粧料または皮膚外用剤 | |
JP2012206971A (ja) | 水中油型乳化組成物 | |
KR20150143850A (ko) | 증점성 조성물 | |
CN109431866A (zh) | 一种含液晶体系的护肤组合物及其制备方法 | |
JP2003292414A (ja) | 油溶性成分安定化組成物及びその組成物を配合した化粧料、並びに油溶性成分の安定化方法 | |
US10226413B2 (en) | Solution solubilization composition of insoluble material and method for solubilizing insoluble material using same | |
Savic et al. | Behind the alkyl polyglucoside-based structures: Lamellar liquid crystalline and lamellar gel phases in different emulsion systems | |
JP5709304B2 (ja) | 水中油型乳化化粧料 | |
JP2009062521A (ja) | ヒアルロン酸プロピレングリコールエステルおよびそれを用いた皮膚外用剤 | |
JP6453665B2 (ja) | 洗浄剤組成物 | |
WO2022163336A1 (ja) | セラミド類含有組成物 | |
CN113648232A (zh) | 承载尿素或其衍生物的稳定组合物 | |
KR20150076477A (ko) | 지속적인 보습 효능을 갖는 오일 세안료 조성물 | |
JP6531514B2 (ja) | 乳化組成物 | |
JP2008088104A (ja) | W/o/w型乳化物及び外用剤及び化粧料 | |
JP2005179241A (ja) | 水中油型用の乳化剤組成物、及び該組成物を含有する化粧料 | |
EP1598044B1 (en) | Oil-in-water emulsion and process for producing the same | |
JP2022062699A (ja) | 皮膚軟化剤および洗浄剤 | |
JP2017214323A (ja) | 肌質改善剤用安定組成物 | |
CN116710041A (zh) | 水性乳液 | |
JPH0563219B2 (ja) | ||
JP2020090454A (ja) | 高内相w/o型乳化組成物及びこれを利用した化粧料 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 22745561 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2022578210 Country of ref document: JP Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 20237025373 Country of ref document: KR Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 202280012429.5 Country of ref document: CN |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 22745561 Country of ref document: EP Kind code of ref document: A1 |